Rep. Cummings: Don't believe Mylan's numbers this year

4:56 PM ET Mon, 26 Sept 2016

Rep. Elijah Cummings (D-Maryland) reacts to the new report saying pre-tax profits on Mylan's EpiPen were 60 percent higher than CEO Heather Bresch told Congress last week. CNBC's Meg Tirrell reports.